Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 5, 2006, Pages 573-584

  Deeg, H Joachim ^a   Storer, Barry E ^a   Boeckh, Michael ^a   Martin, Paul J ^a   McCune, Jeannine S ^a   Myerson, David ^a   Heimfeld, Shelly ^a   Flowers, Mary E ^a   Anasetti, Claudio ^a   Doney, Kristine C ^a   Hansen, John A ^a   Kiem, Hans Peter ^a   Nash, Richard A ^a   O'Donnell, Paul V ^a   Radich, Jerald P ^a   Sandmaier, Brenda M ^a   Scott, Bart L ^a   Sorror, Mohamed L ^a   Warren, E Houston ^a   Witherspoon, Robert P ^a   Woolfrey, Ann ^a   Appelbaum, Frederick R ^a   Storb, Rainer ^a   more..

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Busulfan; Graft versus host disease; Peripheral blood progenitor cells; Thymoglobulin

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; METHOTREXATE; METHYLPREDNISOLONE; PHENYTOIN; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOMONOCYTIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DONOR; DRUG DOSE REGIMEN; EPSTEIN BARR VIRUS; FEMALE; GRAFT SURVIVAL; HUMAN; INCIDENCE; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; RELAPSE; REMISSION; RISK REDUCTION; SCHOOL CHILD; SEIZURE; VIRUS REACTIVATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTILYMPHOCYTE SERUM; BUSULFAN; CAUSE OF DEATH; CHILD; CHRONIC DISEASE; COHORT STUDIES; COMORBIDITY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HERPESVIRUS 4, HUMAN; HUMANS; INCIDENCE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 33745470309     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.12.036     Document Type: Article

References (40)

1. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100 (2002) 1201-1207
2. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine. clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104 (2004) 857-864
3. Guardiola P., Runde V., Bacigalupo A., et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 99 (2002) 4370-4378
4. Nevill T.J., Fung H.C., Shepherd J.D., et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 92 (1998) 1910-1917
5. Sierra J., Pérez W.S., Rozman C., et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100 (2002) 1997-2004
6. Jurado M., Deeg H.J., Storer B., et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant 8 (2002) 161-169
7. Anderson J.E., Appelbaum F.R., Schoch G., et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology. a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 14 (1996) 220-226
8. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission. a randomized trial of two irradiation regimens. Blood 76 (1990) 1867-1871
9. Deeg H.J., Spitzer T.R., Cottler-Fox M., Cahill R., and Pickle L.W. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplant 7 (1991) 193-198
10. Martin P.J., and Kernan N.A. T-cell depletion for GVHD prevention in humans. In: Ferrara J.L.M., Deeg H.J., and Burakoff S.J. (Eds). Graft-vs.-Host Disease (1997), Marcel Dekker, Inc, New York 615-637
11. Bacigalupo A., Sormani M.P., Lamparelli T., et al. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica 89 (2004) 1238-1247
12. Remberger M., Storer B., Ringden O., and Anasetti C. Association between pretransplant Thymogloblulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 29 (2002) 391-397
13. Remberger M., Mattsson J., and Ringden O. Polyclonal anti-T-cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation. Pediatr Transplant 5 (2001) 285-292
14. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation. study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 8 (2002) 468-476
15. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. [erratum appears in Blood 1998;91:1100]. Blood 89 (1997) 2079-2088
16. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia. the influence of plasma busulfan levels on the outcome of transplantation. Blood 89 (1997) 3055-3060
17. Slattery J.T., and Risler L.J. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 20 (1998) 543-549
18. McCaul K.G., Nevill T.J., Barnett M.J., et al. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 9 (2000) 367-374
19. Deeg H.J., Amylon M.D., Harris R.E., et al. Marrow transplants from unrelated donors for patients with aplastic anemia. minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 7 (2001) 208-215
20. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
21. Petersdorf E.W., Longton G.M., Anasetti C., et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 89 (1997) 1818-1823
22. Durnam D.M., Anders K.R., Fisher L., O'Quigley J.O., Bryant E.M., and Thomas E.D. Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay. Blood 74 (1989) 2220-2226
23. Shulman H.M., Wells D., Gooley T., Myerson D., Bryant E., and Loken M.R. The biologic significance of rare peripheral blasts after hematopoietic cell transplantation is predicted by multidimensional flow cytometry. Am J Clin Pathol 112 (1999) 513-523
24. Scharf S.J., Smith A.G., Hansen J.A., McFarland C., and Erlich H.A. Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood 85 (1995) 1954-1963
25. Sievers E.L., Lange B.J., Buckley J.D., et al. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. J Natl Cancer Inst 88 (1996) 1483-1488
26. Boeckh M., Nichols W.G., Papanicolaou G., Rubin R., Wingard J.R., and Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients. current status, known challenges, and future strategies. Biol Blood Marrow Transplant 9 (2003) 543-558
27. Crippa F., Holmberg L., Carter R.A., et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 8 (2002) 281-289
28. Boeckh M., Stevens-Ayers T., and Bowden R.A. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. J Infect Dis 174 (1996) 907-912
29. Carpenter P.A., Appelbaum F.R., Corey L., et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99 (2002) 2712-2719
30. Gooley T.A., Leisenring W., Crowley J., and Storer B.E. Estimation of failure probabilities in the presence of competing risks. new representations of old estimators. Stat Med 18 (1999) 695-706
31. Regan J.F., Lyonnais C., Campbell K., Smith L.V., and Buelow R. Total and active Thymoglobulin levels. effects of dose and sensitization on serum concentrations. Transpl Immunol 9 (2001) 29-36
32. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning. influence of pretransplant comorbidities. Blood 104 (2004) 961-968
33. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index. a new tool for risk assessment before allogeneic HCT. Blood 106 (2005) 2912-2919
34. Martin P., Nash R., Sanders J., et al. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant 21 (1998) 273-279
35. Cutler C., Giri S., Jeyapalan S., Paniagua D., Viswanathan A., and Antin J.H. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation. a meta-analysis. J Clin Oncol 19 (2001) 3685-3691
36. Remberger M., Svahn B.M., Mattsson J., and Ringden O. Dose study of Thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 78 (2004) 122-127
37. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors. 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98 (2001) 2942-2947
38. Bornhäuser M., Storer B., Slattery J.T., et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 102 (2003) 820-826
39. Guardiola P., Anderson J.E., Bandini G., et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia. a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood 93 (1999) 2831-2838
40. Dupriez B., Morel P., Demory J.L., et al. Prognostic factors in agnogenic myeloid metaplasia. a report on 195 cases with a new scoring system. Blood 88 (1996) 1013-1018